<DOC>
	<DOCNO>NCT01045369</DOCNO>
	<brief_summary>The purpose study see use combination drug class , like one Kaletra® Intelence™ belong , still help reduce amount HIV blood . Using Kaletra® Intelence™ without drug approve FDA use study experimental .</brief_summary>
	<brief_title>A Pilot Study Kaletra Intelence Tablets Naive Subjects</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>HIV1 RNA ≥ 5000 copies/mL Roche Amplicor 1.5v Primer More 18 year age Provide write informed consent willingness participate comply Less 7 day prior ART license investigational compound Does currently treat active opportunistic infection ( OI ) within 30 day screen Vital sign , physical examination laboratory result exhibit evidence acute illness A female nonchildbearing potentiator childbearing potential , negative serum pregnancy test screen agree one following : complete abstinence intercourse 2 week prior administration study drug , throughout study , least 2 week completion premature discontinuation study account elimination investigational drug . Should patient decide become sexually active course study , must counsel willing use one birth control method like double barrier method , intrauterine device , sterilization method . NOTE : Data insufficient exclude clinically important interaction LPV/r drug , hormonal contraceptive , highly metabolize cytochrome P450 enzyme system . As result , hormonal contraception consider adequate . Patient active AIDSdefining opportunistic infection 30 day prior baseline , opinion investigator , would preclude patient participate study ( See Appendix C ) . Patient weight genotypic score etravirine ≥3 . ( See Appendix D ) Patient &gt; 3 mutation 10 , 20 , 24 , 32 , 33 , 36 , 46 , 47 , 48 , 50 , 54 , 73 , 82 , 84 , 90 protease ≥1 follow mutation protease ( I47A/V , V32I , L76V ) . History active substance abuse . Pregnant time screen evaluation breastfeeding . Patient , opinion investigator , unlikely able complete 48week dose period protocol evaluation assessment adhere study drug regimen . Serious medical condition , diabetes , congestive heart failure , cardiomyopathy cardiac dysfunction , opinion investigator would compromise safety patient Malabsorption syndrome gastrointestinal dysfunction , may interfere drug absorption render patient unable take oral medication . Undergoing interferon therapy HCV anticipate undergoing therapy course trial HBV coinfection Laboratory result within 30 day prior first dose study medication : Hemoglobin concentration &lt; 8.0 g/dL Absolute neutrophil count &lt; 750 cells/mm3 Platelet count &lt; 50,000 cells/ mm3 Aminotransferase ( AST , ALT ) &gt; 3 time ULN Serum creatinine &gt; 1.5 time Upper Limits Normal ( ULN ) Radiation therapy cytotoxic chemotherapeutic agent within 4 week prior entry , anticipate need agent within study period . Immunomodulating agent , systemic corticosteroid , interleukin , interferon 's within 4 week prior study entry , patient receive HIV immunotherapeutic vaccine within 3 month prior entry . Asthmatic patient use inhaled corticosteroid eligible enrollment . Methadone therapy Foscarnet therapy therapy agent document activity HIV1 vitro . Taking astemizole , terfenadine , cisapride , oral midazolam , triazolam , flecainide , pimozide , propafenone , St. John 's Wort , lovastatin , simvastatin , rifampin ergot derivative . Allergy study drug excipients therein . Patient require inhaled intranasal fluticasone .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>HIV</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>